Abivax (ABVX) Gains from Investment Securities (2024 - 2025)

Abivax's (ABVX) quarterly Gains from Investment Securities came in at $74.0 million in Q3 2025, up 25602.0% year-on-year from N/an in Q3 2024, and up 3350.35% quarter-over-quarter from -$2.3 million in Q2 2025.

Abivax (ABVX) Gains from Investment Securities (2024 - 2025) Analysis & Trends

Abivax's Gains from Investment Securities history runs 2 years deep, the most recent figure standing at $74.0 million for Q3 2025.

  • On a quarterly basis, Gains from Investment Securities rose 25602.0% year-over-year to $74.0 million in Q3 2025; TTM through Mar 2026 was $71.7 million, a 2224.68% increase from a year earlier, with the FY2025 full-year figure at $72.6 million, up 4634.13% from the prior year.
  • Gains from Investment Securities climbed to $74.0 million in Q3 2025 per ABVX's latest filing, from -$2.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $74.0 million in Q3 2025 and bottomed at -$2.3 million in Q2 2025.
Generated on {Timestamp} © BusinessQuant.com
Generated on {Timestamp} Powered by BusinessQuant Logo

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Oculis Holding AG 67,072.09 Bn 67,072.09 Bn -
2 Nanobiotix 1,894.61 Bn 1,894.55 Bn -
3 Akari Therapeutics 1,014.18 Bn 1,014.18 Bn -
4 BeOne Medicines 471.64 Bn 466.85 Bn 1.35 Bn
5 Vertex Pharmaceuticals 121.72 Bn 114.47 Bn 2.59 Bn
6 Regeneron Pharmaceuticals 68.28 Bn 59.52 Bn 3.31 Bn
7 Belite Bio 61.40 Bn 61.40 Bn -
8 Argenx Se 56.94 Bn 56.94 Bn 1.18 Bn
9 Revolution Medicines 37.37 Bn 37.37 Bn -
10 Abivax 9.98 Bn 9.98 Bn -

Historic Data

Download Data
DateValue
Sep 30, 2025 73.95 Mn
Sep 30, 2025 73.95 Mn
Jun 30, 2025 -2.28 Mn
Jun 30, 2025 -2.28 Mn
Mar 31, 2025 1.14 Mn
Mar 31, 2025 1.14 Mn
Dec 31, 2024 -293,863.74
Dec 31, 2024 -293,863.74
Sep 30, 2024 287,733.51
Sep 30, 2024 287,733.51
Jun 30, 2024 1.95 Mn
Jun 30, 2024 1.95 Mn
Mar 31, 2024 -417,162.92
Mar 31, 2024 -417,162.92